AstraZeneca Partners With Oracle to Refine Clinical Research With AI
By Adria Calatayud
AstraZeneca said it is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the pharmaceutical industry.
The U.K. drugmaker said Tuesday that the collaboration aims to leverage Oracle's artificial-intelligence, cloud and data capabilities.
Rather than using AI to discover new drug targets, the companies are looking to test practical ways to connect scientific research directly to clinical workflows, initially exploring clinical-trial recruitment, earlier diagnosis and drug-safety monitoring, AstraZeneca said.
The first program to be launched under the collaboration will focus on hypertension care and clinical research in Abu Dhabi in partnership with healthcare company M42, AstraZeneca said. AstraZeneca added that the collaboration would cover multiple international projects across the U.S., the Middle East, and Europe spanning its core disease areas--cancer, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases.
This marks the latest tie-up between pharma and tech groups, as drugmakers test how to deploy AI to bring new medicines to patients faster and leverage the technology to make their operations more efficient.
AstraZeneca last week said it would partner with startup Insitro to deploy artificial intelligence to explore new treatments for cardiometabolic diseases in a deal valued at up to $1.5 billion. Wegovy maker Novo Nordisk also entered into deals with AI labs Anthropic and OpenAI, as well as Amazon.com, earlier this year.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 20, 2026 02:09 ET (06:09 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
10 Best Blue-Chip Stocks to Buy for the Long Term
United States